These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 37511137)

  • 1. Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures.
    Aldana J; Gardner ML; Freitas MA
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
    Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
    Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
    Ott HM; Graves AP; Pappalardi MB; Huddleston M; Halsey WS; Hughes AM; Groy A; Dul E; Jiang Y; Bai Y; Annan R; Verma SK; Knight SD; Kruger RG; Dhanak D; Schwartz B; Tummino PJ; Creasy CL; McCabe MT
    Mol Cancer Ther; 2014 Dec; 13(12):3062-73. PubMed ID: 25253781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
    McCabe MT; Graves AP; Ganji G; Diaz E; Halsey WS; Jiang Y; Smitheman KN; Ott HM; Pappalardi MB; Allen KE; Chen SB; Della Pietra A; Dul E; Hughes AM; Gilbert SA; Thrall SH; Tummino PJ; Kruger RG; Brandt M; Schwartz B; Creasy CL
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2989-94. PubMed ID: 22323599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
    Mu W; Starmer J; Yee D; Magnuson T
    Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
    Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
    Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination.
    Kogure M; Takawa M; Saloura V; Sone K; Piao L; Ueda K; Ibrahim R; Tsunoda T; Sugiyama M; Atomi Y; Nakamura Y; Hamamoto R
    Neoplasia; 2013 Nov; 15(11):1251-61. PubMed ID: 24339737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The deletion of the protein phosphatase 1 regulator NIPP1 in testis causes hyperphosphorylation and degradation of the histone methyltransferase EZH2.
    Ferreira M; Verbinnen I; Fardilha M; Van Eynde A; Bollen M
    J Biol Chem; 2018 Nov; 293(47):18031-18039. PubMed ID: 30305391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer.
    Chandnani N; Gupta I; Thakkar V; Sarkar K
    Pathol Res Pract; 2023 Nov; 251():154885. PubMed ID: 37862922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
    Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
    Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
    Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
    Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
    Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
    Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis.
    Coward WR; Feghali-Bostwick CA; Jenkins G; Knox AJ; Pang L
    FASEB J; 2014 Jul; 28(7):3183-96. PubMed ID: 24652950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
    Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
    Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The roles of EZH2 in cancer and its inhibitors.
    Liu Y; Yang Q
    Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
    Barsotti AM; Ryskin M; Rollins RA
    Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
    [No Abstract]   [Full Text] [Related]  

  • 19. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
    Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
    Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycomb Repressive Complex 2 in Oncology.
    Guo Y; Yu Y; Wang GG
    Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.